Dublin, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The "Global AI-based Clinical Trials Market by Phase (Phase-I, Phase-II, Phase-III), Application (Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases), End User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Forecast 2023-2030" report has been added to ResearchAndMarkets.com's offering.
The Global AI-based Clinical Trials Market size was estimated at USD 5.43 billion in 2022, USD 5.98 billion in 2023, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.26% to reach USD 11.86 billion by 2030.
The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global AI-based Clinical Trials Market.
The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.
Market Segmentation & Coverage:
This research report categorizes the Global AI-based Clinical Trials Market in order to forecast the revenues and analyze trends in each of following sub-markets:
Based on Phase, the market is studied across Phase-I, Phase-II, and Phase-III. The Phase-II is projected to witness significant market share during forecast period.
Based on Application, the market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurological Diseases or Conditions, and Oncology. The Infectious Diseases is projected to witness significant market share during forecast period.
Based on End User, the market is studied across Academia and Pharmaceutical Companies. The Academia is projected to witness significant market share during forecast period.
Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
The report provides insights on the following pointers:
- Market Penetration: Provides comprehensive information on the market offered by the key players
- Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
- Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
- Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
- Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
- Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
- What is the market size and forecast of the Global AI-based Clinical Trials Market?
- What are the inhibiting factors and impact of COVID-19 shaping the Global AI-based Clinical Trials Market during the forecast period?
- Which are the products/segments/applications/areas to invest in over the forecast period in the Global AI-based Clinical Trials Market?
- What is the competitive strategic window for opportunities in the Global AI-based Clinical Trials Market?
- What are the technology trends and regulatory frameworks in the Global AI-based Clinical Trials Market?
- What is the market share of the leading vendors in the Global AI-based Clinical Trials Market?
- What modes and strategic moves are considered suitable for entering the Global AI-based Clinical Trials Market?
Market Dynamics
Drivers
- Need for artificial Intelligence which helps in boosting and improving clinical trials
- Rising needs to reduce healthcare costs and declining hardware costs
- Increased adoption of AI-based drug development technology by most of the pharmaceutical companies
Restraints
- Lack of personal involvement leading to a rise in unemployment rates
- Possibility of a defective diagnosis
Opportunities
- Technological advancements and innovations in AI-based clinical trials
- Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors
Challenges
- Concerns associated with the adoption of EHR interoperability
Companies Mentioned
- AiCure, LLC
- Aiforia Technologies
- Antidote Technologies, Inc.
- Avantor, Inc.
- BioSymetrics Inc
- Deep 6 AI
- Deep Lens Inc.
- GNS Healthcare
- Halo Health Systems
- Innoplexus AG
- MEDIAN Technologies
- Saama Technologies, LLC
- Simplifai AS
- Trials.ai, Inc.
- Unlearn.AI, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/w06joi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
